請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50076
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃貴薰(Guey-Shiun Huang) | |
dc.contributor.author | Chiung-Hui Huang | en |
dc.contributor.author | 黃瓊慧 | zh_TW |
dc.date.accessioned | 2021-06-15T12:29:09Z | - |
dc.date.available | 2025-08-17 | |
dc.date.copyright | 2020-09-02 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-17 | |
dc.identifier.citation | 一、 中文部分 中華民國統計資訊網(2016).統計分析.取自https://www.stat.gov.tw/public/Attachment/7911117100ZT9Y70G.pdf 王惠美、趙慧玲、黃薇瑄、廖婉君、胡曉珍、陳德、于博芮(2014).一般外科病患術後傷口換藥疼痛改善專案.領導護理,15(3),96-107。 台灣衛生福利部食品藥物管理署TFDA.(2016).衛部藥輸字第026968號.取自https://www.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic LicId=52026968 台灣癌症登記資料庫Taiwan Cancer Registry Database(2016).行政院衛生福利部國民健康署.取自http://tcr.cph.ntu.edu.tw/main.php?Page=A6 李昭憲、楊燦、賴家欣、鄭麗櫻(2014).探討骨科患者內固定復位手術前後焦慮感及其相關因素之研究.美和學報,33(1),95-107。 吳明隆、涂金堂(2013).SPSS與統計應用分析.台北:五南。 林幸蓉(2008).一位肝癌患者手術前後之護理經驗.慈濟護理雜誌,7(5),95-103。 徐偉勛、李日翔、林家齊、楊志新(2014).肺癌嶄新標靶治療研究現況.台灣醫學,18(6),7。 陳怡伶、陳芃婷、陳姵樺(2012).台灣生物晶片產業競爭力分析.生物產業科技管理叢刊,3(1),61-92。 健康九九網站菸害防治網(2013).行政院衛生福利部國民健康署.取自https://health99.hpa.gov.tw/Tobacco/Show.aspx?MenuId=764 彭姿蓉、李銘嘉、吳大圩(2015).EGFR-TKIs 用於晚期非小細胞肺癌.藥學雜誌,31 (2)。 張聖如、陳國嘉(2016).生物晶片市場發展策略之研究.華人前瞻研究,12(1),99-113。 蔡俊明(2014).圖解肺癌診治照護全書.台灣:原水。 蔡惠華、馮容莊(2012).臺北市某區域型醫院護理過程決策輔助系統之建置.北市醫學雜誌,16(3)244-254。 謝柏宏(2017).楊泮池:在對的時間選對的藥給對的病患.取自 https://m.commonhealth.com.tw/article/article.action?nid=74221 謝詩菡、蕭玉玫、廖婉君、楊雅萍(2015).一位扁桃腺癌末病患瀕臨死亡之護理經驗.高雄護理雜誌,31(1),41-52。 蘇剛毅、何肇基、俞松良、施金元、楊泮池(2014).分子診斷檢測,仍可區分出不同的基因變異.台灣醫學,18(6)。 二、 英文部分 American Cancer Society. (2017). AJCC Cancer Staging Manual. Retrieved from https://cancerstaging.org/references-tools/deskreferences/Documents/AJCC207th%20Ed%20Cancer%20Staging%20Manual.pdf American Cancer Society. (2017). Non-Small Cell Lung Cancer Stages. Retrieved from https://www.cancer.org/cancer/non-small-cell-lung- cancer/detection-diagnosis-staging/staging.html Bosc C., Ferretti G. R., Cadrane J., Audigier-Valette C., Besse B., Barlesi F., Decroisette C., Lantuejoul S., Arbib F., Moro-Sibilot D.. (2015). Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol, 10(2): 247-253. Cancer Statistics - National Cancer Institute. (2016). National Cancer Institute. Retrieved from https://www.cancer.gov/about-cancer/understanding/statistics Centers for Disease Control and Prevention. (2017). What Are the Risk Factors Retrieved from https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm Cesare Gridelli, Antonio Rossi, David P. Carbone, Juliana Guarize, Niki Karachaliou, Ribeiro N. C., Barreto S. C., Hora E. C., de Sousa R. M.. (2011). The nurse providing care to trauma victims in pain: the fifth vital sign. Rev Esc Enferm USP, 45(1):146-152. Cesare Gridelli, Antonio Rossi1, David P. Carbone, Juliana Guarize, Niki Karachaliou, Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell. (2015). Non-small-cell lung cancer. Nature Reviews Disease Primers, 1:01-16. Ching Hu Chung. (2019). EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. Oncology Letters, 18(6): 6090-6100. ClinicalTrials.gov. (2018). AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA) Retrieved from https://clinicaltrials.gov/ct2/show/NCT02296125 ClinicalTrials.gov. (2016). AZD9291 First Time In Patients Ascending Dose Study (AURA) Retrieved from https://clinicaltrials.gov/ct2/show/NCT01802632 Daniel Morgensztern, Meghan J. Campo, Suzanne E. Dahlberg, Robert C. Doebele, Edward Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca Heist, Thomas Hensing, Leora Horn, Suresh S. Ramalingam, Charles M. Rudin, Ravi Salgia, Lecia Sequist, Alice T. Shaw, George R. Simon, Neeta Somaiah, David R. Spigel, John Wrangle, David Johnson, Roy S. Herbst, Paul Bunn, Ramaswamy Govindan. (2015). Molecularlya Targeted Therapies in Non-Small Cell Lung Caner Annual Update 2014, J Thorac Oncol, 10(101): S1–63. Du L., Morgensztern D.. (2015). Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer. Cancer J., 21(5): 366-370. E. K. Goag, J. M. Lee, K. S. Chung, S. Y. Kim, A. Y. Leem, J. H. Song, J. Y. Jung, M. S. Park, Y.S. Chang, Y. S. Kim, J. Chang, E. Y. Kim. (2018). Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor. J Cancer, 2(6): 1113-1120. Ellis P. M.. (2016). Anti-angiogenesis in Personalized Therapy of Lung Cancer. Adv Exp Med Biol, 893:91-126. Food and Drug Administration. (2018). Recently Approved Devices. Retrieved from https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-cdx-p170019 Fujimoto J., Wistuba II. (2014). Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol, 31(4):306-313. Gadgeel S., Thakur M.. (2016). Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 37(05), 760-770. Garinet S., Laurent-Puig P., Blon, H., Oudart J.. (2018). Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? Journal of Clinical Medicine, 7(6):144. Giroux Leprieur E., Fallet V., Cadranel J., Wislez M.. (2016). Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: Patients selection and perspectives. Lung Cancer (Auckl), 17(7):83-90. Goldstraw P.. (2013). New TNM classification: achievements and hurdles. Trans Lung Cancer Res, 2(4): 264-272. Goldstraw P., Chansky K., Crowley J., Rami Porta R., Asamura H., Eberhardt W. E., Nicholson A.G., Groome P., Mitchell A., Bolejack V.; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. (2016). The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 11(1):39-51. H. Wang, L. Zhang, X. Si., X. Zhang, M. Wang. (2018). Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 11: 7513-7519. Hata A., Katakami N., Nanjo S., Okuda C., Kaji R., Imai Y.. (2017). Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo, 31(3): 475-479. Jekunen A. P.. (2015). Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol, 1-11. Karachaliou N., Rosell R., Morales-Espinosa D., Viteri S.. (2014). Systemic treatment in EGFR-ALK NSCLC patients: Second line therapy and beyond. Expert Review of Anticancer Therapy, 14(7): 807-815. Khan M.F., Straub R., Moghaddam S. R.. (2008). Variables affecting the risk of pneumothorax and intrapulmonal hemorrhage in CT-guided transthoracic biopsy. Eur Radiol, 18(7):1356-1363. Kim D., Kim D. H.. (2018). Epigenome-Based Precision Medicine in Lung Cancer. Methods Mol Biol, 1856: 57-85. Kim J. H., Kim Y. T. Lim, H. K. Kim Y. H., Sung S. W.. (2013). Management for chest wall implantation of non-small cell lung cancer after fine-needle aspiration biopsy. Eur J Cardiothorac Surg, 23(5), 823-832. Kim T.-O., Oh I. J., Kho B. G., Park H. Y., Chang J. S., Park C. K., Shin H. J., Lim J. H., Kwon Y. S., Kim Y. I., Lim S. C., Kim Y. C., Choi Y. D.. (2018). Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer. Thorac Cancer, 9(7): 856-864. Kovács E., Prókai L., Mészáros L., Gondos T.. (2013). Adapted physical activity is beneficial on balance, functional mobility, quality of life and fall risk in community-dwelling older women: a randomized single-blinded controlled trial. Eur J Phys Rehabil Med, 49(3): 301-310. Kovács Z., Szabó C., Fülöp E.. (2013). Therapy helps psychosocial support for patients diagnosed with breast cancer, reducing anxiety and depression. Psychiatr Hung, 28(4): 454-463. Leprieur E. G., Fallet V., Cadranel J., Wislez M.. (2016). Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: Patients selection and perspectives. Lung Cancer: Targets and Therapy, 7: 83-90. Liao, B., Lin, C., Lee, J., Yang, J. C. (2018). Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors. Journal of the Formosan Medical Association, 117: 326-331. Lindeman N. I., Cagle P. T., Beasley M. B., Chitale D. A., Dacic S., Giaccone G., Jenkins R. B., Kwiatkowski D. J., Saldivar J. S., Squire J., Thunnissen E., Ladanyi M.. (2013). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 8(7):823-859. Liseth L. van den Berg, Theo J. Klinkenberg, Harry J. M. Groen, Joachim Widder. (2015). Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC. Journal of Thoracic Oncology, 10(5):826-831. Lovly C., L. Horn, W. Pao. (2016). Molecular Profiling of Lung Cancer. My Cancer Genome website. http://www.mycancergenome.org/content/disease/lung-cancer. McCoach C. E., Jimeno A.. (2016). A third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR Thr790Met mutations. Drugs Today (Barc), 52(10):561-568. Mcmullen S., Hess L. M., Kim E. S., Levy B., Mohamed M., Waterhouse D., Wozniak A., Goring S., Müller K., Muehlenbein C., Zhu Y., Oton B. A., Ersek L. A., Winfree, K. B. (2018). Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy. The Patient - Patient-Centered Outcomes Research, 12(2): 223-233. M. H. Hong, H. R. Kim, B. C. Ahn, S. J. Heo, J. H. Kim, B. C. Cho. (2019). Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer. Yonsei Med J, 60(6): 525-534. Mills M., Choi J., El Haddad G., Sweeney J., Biebel B., Robinson L., Antonia S., Kumar A., Kis B.. (2017). Retrospective analysis of technical success rate and procedure-related complications of 867 percutaneous CT-guided needle biopsies of lung lesions. Clin Radiol. 72(2): 1038-1046. Naylor E. C., Desani J. K., Chung P. K.. (2016). Targeted Therapy and Immunotherapy for Lung Cancer. Surg Oncol Clin N Am, 25(3): 601-609. Nosaki K., Satouchi M., Kurata T., Yoshida T., Okamoto I., Katakami N., Imamura F., Tanaka K., Yamamoto N., Kato T., Kiura K., Saka H., Yoshioka H., Wantanabe K., Mizuno k., Seto T.. (2016). Re-biopsy status among non-small-cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 101: 1-8. Pane Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi (2013). Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 8(7) : 823-859 Paul C. Boyes, A. Hall, A. Bisquera, A. Miller, A.. O’Brien L.. (2016). The impact of cancer diagnosis and treatment on employment, income, treatment decisions and financial assistance and their relationship to socioeconomic and disease factors. Supportive Care in Cancer, 24(11): 4739-4746. Rotow J., Bivona T. G.. (2017). Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer, 127(11):637-658. Satouchi, TakayasuKurata, TatsuyaYoshida, IsamuOkamoto, NobuyukiKatakami, FumioImamura, KaoruTanaka, YukiYamaneiNobuyuk, Yamamoto, TerufumiKato, KatsuyukiKiura, HideoSaka, HiroshigeYoshioka, KanaWatanabe, KeikoMizuno, TakashiSeto. (2016). Re-biopsy status among non-small-cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 101 (2016): 1-8. Schiller J. H., Harrington D., Belani C. P., Langer C., Sandler A., Krook J., Zhu J., Johnson Travis W. D., Brambilla E., Nicholson A. G., Yatabe Y., Austin J. H. M., Beasley M. B., Chirieac L. R., Dacic S., Duhig E., Flieder D. B., Geisinger K., Hirsch F. R., Ishikawa Y., Kerr K. M., Noguchi M., Pelosi G., Powell C. A., Tsao M. S., Wistuba I., WHO Panel. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic. Clinical and Radiologic Advances Since the 2004 Classification. Journal of Thoracic Oncology, 10(9): 1243-1260. Schiller J. H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H., Eastern Cooperative Oncology Group. (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Eng J Med, 346:92-8. Sellmann L., Fenchel K., Dempke W. C.. (2015) Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment? Trans Lung Cancer Res, 4(3): 223-227 Sharma N., Graziano S.. (2018). Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. Cancer Treat Rev, 69: 143-151. Sinner W. N., Zajicek J.. (1976). Implantation Metastasis after Percutaneous Transthoracic Needle Aspiration Biopsy. Acta Radiologica. Diagnosis, 17(4): 473-480. Suresh H. Advani, Hemant Malhotra, Raju Titus Chacko, Maheboob Basade, Pavithran Keechilat, P. N. Mahapatra, Chanchal Goswami, T. P. Sahoo, Chirag Shah. (2017). Advanced therapeutic options and importance of rebiopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed non-small-cell lung carcinoma patients: An expert opinion. Indian J Cancer, 54 (Supplement) : S31-S36. Takahisa Kawamura, Hirotsugu Kenmotsu, Tetsuhiko Taira, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Takashi Nakajima, Yasuhisa Ohde, Masahiro Endo, Toshiaki Takahashi. (2016). Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure: Cancer Sci. 2016 Jul; 107(7): 1001–1005. Targeted Oncology. (2019). 2018 FDA Approvals of Targeted Therapies. Retrieved from https://www.targetedonc.com/publications/targeted-therapy-news/2019/jan-2019/2018-fda-approvals-of-targeted-therapies Tony Mok, Francesco Petrella, Lorenzo Spaggiari, Rafael Rosell. (2015). Non-small-cell lung cancer. Nature Reviews Disease Primers, 1: 15009. Uramoto H., Tanaka F.. (2014). Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res, 3:242-249. Vargas AJ., Harris CC.. (2016). Biomarker development in the precision medicine era: lung cance6r as a case study. Nat Rev Cancer, 16(8):523-537. Vigneswaran J., Tan Y. H., Murgu S. D., Won B. M., Patton K., Villaflor V. M., Hoffman P. C., Hensing T., Hogarth D. K., Malik R., MacMahon H., Mueller J., Simon C. A., Vigneswaran W. T., Wigfield C. H., Ferguson M. K., Husain A. N., Vokes E. E., Salgia R.. (2016). Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget, 7(14): 18876-18886. Villanueva N., Bazhenova L.. (2018). New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis, 12: 1-29. William Pao, Nicolas Girard. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol. Sebastian, 12(2):175-80. Y. T. Lin, C. J. Yu, J. C. Yang, J. Y. Shih. (2016). Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer, 17(5):e77-e94. Yuri Sheikine, Deepa Rangachari, Danielle C. McDonald, Mark S. Huberman, Erik S. Folch, Paul A. VanderLaan, Daniel B. Costa. (2016). EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review. Clinical Lung Cancer, 17(6): 483-492. Zarogoulidis P., Kosmidis C., Fyntanidou V., Aidoni Z., Tsakiridis K., Koulouris C., Michalopoulos N., Barmpas A., Huang H., Bai C., Hohenforst-Schmidt W., Sapalidis K.. (2019). Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods. Lung Cancer Manag, 8(3): LMT16. Zarogoulidis P., Papadopoulos V., Maragouli E., Papatsibas G., Huang H.. (2017). Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer? J Thorac Dis, 9(9): 2771-2773. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50076 | - |
dc.description.abstract | 研究背景:2018年台灣癌症發生率及死亡率首位皆是肺癌。目前肺癌病患最常使用的標靶治療為表皮生長因子接受器-酪胺酸酶抑制劑(EGFR-TKIs)。病患為了確認肺癌是否產生抗藥性,需要接受再次病理切片(re-biopsy),但臨床上並非每位病患都願意接受。
研究目的:藉由此研究了解病患在接受再次病理切片前或切片之後可能會產生何種併發症及相關護理問題,提供照護此類病患面對接受再次病理切片決定時之參考。 研究方法:利用橫斷式(cross-sectional study)、回溯性(retrospective study),收集台 北某醫學中心西元2012至2017年癌症登記資料庫中確診為非小細胞肺癌 (NSCLC) 病患,而回顧其病歷資料。 研究結果:此研究對象共71人,有68人(95.8%,N=71)完成檢測,其中34人(50.0%,N=68)帶有EGFR-Thr790Met 突變,有服用第三代標靶藥物osimertinib者共16人(47.1%,N=34)。27人(38.0%,N=71)有併發症現象產生,以肺炎(10人,14.1%)最多。有關護理問題部分,接受切片前(68人,95.8%)及切片後(70人,98.6%),皆有相關護理需求。接受再次病理切片前的前三名護理問題分別為潛在危險性感染與焦慮皆為46人次(64.8%)、潛在危險性跌倒22人次(31.0%);接受再次病理切片後的前三名護理問題為焦慮49人次(69.0%)、潛在危險性感染46人次(64.8%)、潛在危險性跌倒30人次(42.3%)。 研究結論與應用:共71人住院接受re-biopsy,16人服用第三代標靶藥物osimertinib。Re-biopsy後併發症以肺炎(14.1)最多;切片前與切片後之常見護理問題皆為潛在危險性感染與焦慮、潛在危險性跌倒。 本研究可提供醫護人員及晚期非小細胞肺癌病患,在病情產生變化時考量是否接受re-biopsy,或是檢測出抗藥性基因突變時是否選擇第三代標靶藥物,多一項重要衛教參考資料。 | zh_TW |
dc.description.abstract | Background: Lung cancer is the major incidence and mortality of cancer types in Taiwan, in 2018. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) is most commonly used to treat lung cancer. In order for patients to identify secondary mutations that are resistant to the first treatment, it is important to check whether the lung cancer has produced new mutations. However, not every patient is willing to undergo re-biopsy clinically. Re-biopsy is essential to check whether the lung cancer has produced drug resistance mutations.
Purpose: Re-biopsy is essential to check whether the lung cancer has developed EGFR-TKIs resistant mutations. However, no research has been conducted on the complications and nursing health problems of patients with EGFR-TKIs resistant mutation-positive non-small cell lung cancer (NSCLC) pretreated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Method: This is a retrospective, case-control, and cross-sectional, Taiwanese study. We reviewed medical records of patients with non-small cell lung cancer (NSCLC) pretreated with EGFR-TKIs who treated between January 2012 and Aug 2017 at the medical center in Taipei. Result: Of 71 patients, 68 (95.8%, N = 71) were successful re-biopsy, of which 34 (50.0%, N = 68) developed EGFR-Thr790Met mutation, and 16 (47.1%, N = 34) treated by the third-generation target therapy (osimertinib), 27 (38.0%, N = 71) had re-biopsy-related complications, and the most common was pneumonia in 10 (14.1%). There are nursing health problems that before and after the re-biopsy were the risk for infection and anxiety, and the risk for falls (22, 31.0%); the top three nursing health problems after re-biopsy were the risk for anxiety (49, 69.0%), the risk for infection (46, 64.80%) and falls (30, 42.3%). Discussion and application: Seventy-one patients received re-biopsy, and 16 of them treated by osimertinib using the third-generation EGFR-TKI. The incidence of pneumonia in complications was increased. These are important information that can contribute towards the quality of medical and nursing care provided to lung cancer patients receiving re-biopsy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:29:09Z (GMT). No. of bitstreams: 1 U0001-1108202016343100.pdf: 2902351 bytes, checksum: 5dfc4c1cf9a6ac7d7617af22994d5df9 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 致謝 i 中文摘要 ii Abstract iii 目錄 iv 圖目錄 vi 表目錄 vii 第一章 緒論 1 第一節 研究動機與重要性 1 第二節 研究目的 3 第三節 研究問題 4 第四節 名詞定義 5 第二章 文獻回顧 6 第一節 肺癌現況與簡介 6 第二節 肺癌再次病理切片之目的與重要性 18 第三節 肺癌再次病理切片之併發症 20 第四節 肺癌再次病理切片之護理相關問題 21 第三章 研究方法 23 第一節 研究概念與架構 23 第二節 研究設計 24 第三節 研究場所及研究對象 25 第四節 研究工具 26 第五節 研究資料收集過程 30 第六節 研究資料處理與分析方法 32 第七節 倫理考量 33 第四章 研究結果 34 第一節 研究對象之基本屬性 34 第二節 研究對象接受再次病理切片之現況 41 第三節 研究對象之人口學特性與接受再 次病理切片關聯性分析 48 第四節 研究對象之疾病、治療狀況與接受再次病理切片關聯性分析 50 第五章 討論 59 第一節 研究對象接受再次病理切片之探討 59 第二節 研究對象併發症之探討 62 第三節 研究對象接受切片前後護理問題之探討 64 第四節 肺癌病患re-biopsy未來趨勢 66 第六章 結論與建議 67 第一節 結論 67 第二節 研究限制與建議 68 參考文獻 71 一、 中文部分 71 二、 英文部分 73 附錄 81 附件一 台灣大學附設醫院倫理委員會許可函 81 附件二 個案資料篩選表 84 附件三 個案資料記錄表 85 附件四 AJCC Cancer Staging Manual, 8th Edition 97 圖目錄 Figure 2. 1 非小細胞肺癌基因突變比率圖 10 Figure 2. 2 Non-Small Cell Lung Cancer EGFR Mutation 12 Figure 2. 3 EML4-ALK signaling pathways and potential mechanisms of resistance to targeted therapies 12 Figure 3. 1 研究概念架構 23 Figure 3. 2 收集晚期非小細胞肺癌資料流程 31 Figure 4. 1 收集研究對象人數流程 36 表目錄 表2.1 肺癌分期表 8 表3.1 生活品質評估表(ECOG performance status) 27 表4.1 研究對象之人口學特性分布表 37 表4.2 研究對象之初診斷癌症相關資料分布表 38 表4.3 研究對象之相關肺癌治療分布表 39 表4.4 研究對象之相關共病症因子資料分布表 40 表4.5 研究對象再次病理切片相關資料分布表 43 表4.6 研究對象接受common EGFR mutation 接受1st TKIs產生藥物耐受性比例 44 表4.7 研究對象切片後併發症分布表 45 表4.8 研究對象切片前後之相關護理問題個數與人數分布表 46 表4.9 研究對象人口學變項與其切片後併發症相關表 49 表4.10 研究對象人口學變項與其切片前護理問題相關表 49 表4.11 研究對象人口學變項與其切片後護理問題相關表 49 表4.12 研究對象癌症相關資料與其切片後併發症相關表 51 表4.13 研究對象肺癌治療史與其切片後併發症相關表 52 表4.14 研究對象肺癌再次病理切片相關因子與其切片後併發症相關表 53 表4.15 研究對象癌症相關資料與其切片前護理問題相關表 54 表4.16 研究對象癌症相關資料與其切片後護理問題相關表 55 表4.17 研究對象肺癌治療史與其切片前護理問題相關表 56 表4.18 研究對象肺癌治療史與其切片後護理問題相關表 57 表4.19 研究對象相關因子與其切片前護理問題相關表 58 表4.20 研究對象肺癌再次病理切片相關因子與其切片後護理問題相關表 58 | |
dc.language.iso | zh-TW | |
dc.title | 探討具有基因突變之晚期非小細胞肺癌病患再次接受病理切片現況–以台灣某醫學中心為例 | zh_TW |
dc.title | Exploring the Non-Small Cell Lung Cancer Patients withGenetic Mutations Received Re-riopsy at a Medical Center in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張榮珍(Jung-Chen Chang),陳冠宇(Kuan-Yu Chen) | |
dc.subject.keyword | 併發症,EGFR-TKIs 抗藥性,肺癌,護理問題,再次病理切片, | zh_TW |
dc.subject.keyword | complication,EGFR-TKIs resistance,lung cancer,ursing health problem,re-biopsy, | en |
dc.relation.page | 97 | |
dc.identifier.doi | 10.6342/NTU202002977 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 護理學研究所 | zh_TW |
顯示於系所單位: | 護理學系所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1108202016343100.pdf 目前未授權公開取用 | 2.83 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。